Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | London | Healthcare | Pharmaceuticals | £246.50B | 79.7x | -3.07 | GBX 16,083.24 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £226.33B | 18.6x | 0.96 | GBX 5,104 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £203.66B | 26.5x | -0.88 | GBX 25,552.91 | -9.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £203.66B | 26.5x | -0.87 | GBX 24,276.38 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £167.60B | 17x | -1.3 | GBX 8,664.21 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £165.08B | 28.8x | 1.21 | GBX 10,654 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.3% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £153.11B | 11.8x | 0.02 | GBX 6,103.39 | 8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £102.03B | 22.9x | 0.02 | GBX 8,201.64 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £89.19B | 17x | 0.41 | GBX 7,331.89 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £55.28B | 17.7x | -0.57 | GBX 1,370 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.6% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £41.87B | 17.2x | 4.65 | GBX 9,636.97 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £31.90B | 23.7x | 0.56 | GBX 359.70 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.8% Upside | Upgrade to Pro+ | |
UCB L | London | Healthcare | Pharmaceuticals | £28.95B | 31.2x | 0.14 | GBX 15,241.57 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £24.12B | -8.6x | 1.79 | GBX 2,454.07 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £18.62B | GBX 4,408.04 | 65.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Biogen | London | Healthcare | Pharmaceuticals | £13.96B | 12.5x | 0.47 | GBX 9,527.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £9.41B | 26x | 3.42 | GBX 4,573.77 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £8.64B | 26.3x | 0.41 | GBX 6,120.02 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.74B | 25.2x | -0.52 | GBX 9,381.43 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £7.37B | 21.6x | 0.21 | GBX 2,142.12 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | £6.21B | 37x | GBX 1,023.03 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Grifols Pref | London | Healthcare | Pharmaceuticals | £6.21B | 37x | GBX 735.35 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £4.92B | 45.8x | 0.72 | GBX 2,228.47 | 28.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £4.40B | 16.7x | 0.18 | GBX 1,995 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.1% Upside | Upgrade to Pro+ | |
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | £4.06B | 41.2x | 1.35 | GBX 29,100.90 | 38.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
H Lundbeck L | London | Healthcare | Pharmaceuticals | £3.80B | 11.6x | 0.27 | GBX 394.16 | -80.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | £3.26B | 57.9x | 0.27 | GBX 5,502.98 | 36.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | £2.62B | 20.9x | 0.98 | GBX 31,487.99 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | £2.26B | 82.3x | -1.17 | GBX 263.81 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.3% Upside | Upgrade to Pro+ | |
Almirall | London | Healthcare | Pharmaceuticals | £1.97B | 92.9x | GBX 917.82 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Indivior PLC | London | Healthcare | Pharmaceuticals | £1.50B | -34x | 0.07 | GBX 1,198.62 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.3% Downside | Upgrade to Pro+ | |
Fagron NV | London | Healthcare | Pharmaceuticals | £1.40B | 20.1x | 1.45 | GBX 1,923.06 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faes Farma | London | Healthcare | Pharmaceuticals | £1.24B | 13.1x | GBX 398.47 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Pharma Mar | London | Healthcare | Pharmaceuticals | £1.21B | 53.3x | GBX 6,895.31 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Cosmo Pharmas | London | Healthcare | Pharmaceuticals | £905.76M | 8.1x | 0.01 | GBX 5,664.95 | 11.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Uniphar | London | Healthcare | Pharmaceuticals | £839.92M | 11x | 0.35 | GBX 322 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.3% Upside | Upgrade to Pro+ | |
Biogaia AB | London | Healthcare | Pharmaceuticals | £781.92M | 35.2x | -1.2 | GBX 773.37 | -80.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medincell | London | Healthcare | Pharmaceuticals | £463.64M | GBX 1,400.15 | 84.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Niox PLC | London | Healthcare | Pharmaceuticals | £283.94M | 83.9x | -1.33 | GBX 69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
Beximco Pharma. | London | Healthcare | Pharmaceuticals | £271.13M | 7x | 0.25 | GBX 40.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Animalcare | London | Healthcare | Pharmaceuticals | £201.45M | 37.1x | 0.03 | GBX 292 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
Santhera Pharmas Holding | London | Healthcare | Pharmaceuticals | £169.10M | -3.8x | 0.03 | GBX 1,315.61 | 45.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Photocure | London | Healthcare | Pharmaceuticals | £119.48M | 776.2x | -14 | GBX 449.88 | 16.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Venture Life Group | London | Healthcare | Pharmaceuticals | £71.71M | -2,800x | 19.35 | GBX 56 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eco Animal | London | Healthcare | Pharmaceuticals | £52.05M | 30.9x | 0.51 | GBX 76.81 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRUSHMETRIC | Aquis Exchange | Healthcare | Pharmaceuticals | £30.51M | -4.5x | GBX 0.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Probiotix | Aquis Exchange | Healthcare | Pharmaceuticals | £15.82M | -13x | GBX 0.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Oxford Biodynamics | London | Healthcare | Pharmaceuticals | £9.98M | -0.2x | -0.01 | GBX 0.51 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oasmia Pharma | London | Healthcare | Pharmaceuticals | £9.71M | -3.2x | -0.05 | GBX 1.77 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Celadon Pharmaceuticals | London | Healthcare | Pharmaceuticals | £9.23M | -3.9x | GBX 13.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |